Liquidia Q2 revenue jumps on YUTREPIA sales
LQDA•YUTREPIA adoption and outlook
The company said YUTREPIA adoption continued to expand, with about 5,900 unique patient prescriptions and more than 5,000 patients treated since launch.
Liquidia also said its prescriber base has exceeded 1,100 since launch, with over 30% prescribing to at least five patients.
The company did not provide specific financial guidance for upcoming quarters or the full year.
Quarterly results and revenue growth
Liquidia's second-quarter sales revenue rose sharply on YUTREPIA sales, with the company saying higher sales volume of the drug drove the increase.
The company reported:
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | $171.68 mln | ||
| Q2 EPS | Meet | $0.74 | $0.74 (8 analysts) |
| Q2 Net Income | $74.72 mln | ||
| Q2 Operating Income | $85.52 mln |
Liquidia said it posted a fourth consecutive quarter of profitability.
Related News
Lexeo Therapeutics releases corporate presentation outlining cardiac gene therapy pipeline, AAVrh.10 platform
LXEO•
Black Rock Coffee Bar, Inc. <BRCB.O>: Raymond James Cuts Target Price to $13 From $18
BRCB•
